A pilot randomized placebo-controlled study on modified MaZiRenWan: a formulated Chinese medicine to relieve constipation for palliative cancer patients

Chung Wah Cheng, Hoi Fung Mok, Cora W. S. Yau, Jasmine T. M. Chan, Yu Chen Kang, Pui Yan Lam, Linda L. D. Zhong, Chen Zhao, Bacon F. L. Ng, Annie O. L. Kwok*, Doris M. W. Tse*, Zhao Xiang Bian*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background

Constipation is a common problem among advanced cancer patients; however, many of them find limited effective from current therapies. Thus, we aimed to test the effect of a traditional Chinese herbal formula, modified MaZiRenWan (MZRW), by comparing with placebo among palliative cancer patients with constipation. 

Methods

This is a randomized, double-blind, placebo-controlled trial. Participants aged over 18 were recruited and randomized to MZRW or placebo group in addition to current prescriptions (including ongoing laxatives treatment) for two weeks. Exclusion criteria included cognitive impairment, presence of a colostomy or gastrointestinal obstruction and estimated life expectancy of less than one month. Individualized modification of MZRW was allowed according to the traditional Chinese medicine (TCM) pattern of patient. The primary outcome was the global assessment of improvement, which reflected whether the constipation had improved, remained the same or worsened. 

Results

Sixty patients, with mean age 75.2 years (range 47–95 years), were randomized to MZRW or placebo group. Among the MZRW group, 59.3% (16/27) had improvement in the global assessment score, as compared with 28.6% (8/28) of the placebo group (p-value = 0.022). Besides, the MZRW group had significant increase in stool frequency, and reduction in constipation severity and straining of defecation (p-value < 0.05). No serious adverse event was reported due to the research medication. 

Conclusion

This pilot trial suggests modified MZRW is well-tolerated and effective for relief of constipation in patients with advance cancer. It could be considered as a potential treatment option for constipation in palliative care. 


Original languageEnglish
Article number31
JournalChinese Medicine (United Kingdom)
Volume17
Issue number1
Early online date2 Mar 2022
DOIs
Publication statusE-pub ahead of print - 2 Mar 2022

Scopus Subject Areas

  • Pharmacology
  • Complementary and alternative medicine

User-Defined Keywords

  • Constipation
  • MaZiRenWan
  • Palliative care
  • Placebo
  • Randomized controlled trial
  • Traditional Chinese Medicine

Fingerprint

Dive into the research topics of 'A pilot randomized placebo-controlled study on modified MaZiRenWan: a formulated Chinese medicine to relieve constipation for palliative cancer patients'. Together they form a unique fingerprint.

Cite this